Peptide education
NAD+
NAD plus · Nicotinamide adenine dinucleotide · beta-NAD · Oxidized NAD
NAD+ is nicotinamide adenine dinucleotide, a coenzyme every cell uses to move electrons and feed enzymes like sirtuins, PARPs, and CD38. It is not a peptide and has no amino-acid sequence; it appears on this site because the same clinics and vendors that sell peptides sell NAD+ drips, shots, and sprays beside them. The biochemistry is real, and NAD+ levels do fall with age. What has never been shown is that a clinic infusion, injection, or oral product turns that biology into more energy, sharper cognition, slower aging, or any of the other marketed outcomes.
The entire published human record for NAD+ products is two small IV studies: one watched metabolites move, one tracked tolerability. Neither measured a single benefit the clinics advertise.
Overview
Quick answer
NAD+ biology is real, but a clinic drip, injection, nasal spray, oral product, or research-use vial is a product claim, not the same thing as cellular biochemistry. The molecule's basic role in cells has to be separated from trial registries, FDA compounding materials, and commercial wellness claims.
What is it?
NAD+ is the oxidized half of the NAD+/NADH pair, a coenzyme that carries electrons through energy metabolism and gets consumed by enzymes involved in stress signaling, DNA-damage responses, and inflammation biology. Essential to cells; that part is not in dispute.
Why does it show up with peptides if it is not a peptide?
Same shelf, same pitch. The clinics and vendors that sell mitochondrial peptides place NAD+ beside MOTS-c, SS-31, and glutathione under a cellular-energy banner. The grouping is a marketing fact, not a scientific one.
What do people use or discuss it for?
Energy, brain fog, recovery, detox, addiction support, anti-aging, and general wellness. The published human record is two small IV studies and a couple of disease-specific trial registrations, none of which tested any of those claims.
What route and dose details do sources report?
The two concrete human exposures are IV: 750 mg infused over six hours in one pilot, and 500 mg daily for four days in a retrospective clinic review. Clinics commonly sell 250 to 750 mg infusions run slowly over one to four hours; oral precursors like NR and NMN are a separate, better-documented route for raising NAD+ levels.
What is the practical takeaway?
The jump that matters is from "NAD+ matters in cells" to "this drip helps you," and nobody has made that jump with data. With FDA also flagging sterility and endotoxin problems in compounded injectable NAD+, the product question matters more than the molecule question.
Reported practice
Commonly reported protocol
Clinic IV infusion programs. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
PubChem identifies beta-nicotinamide adenine dinucleotide as a chemical entity. That supports treating NAD+ as a coenzyme topic rather than a peptide sequence.
Public human sources include small IV NAD+ studies and disease-specific trial registries. They show what has actually been studied, but not broad wellness benefits or route-switching claims.
FDA materials describe ingredient suitability, supplier quality, sterile compounding, endotoxin, and facility oversight concerns involving NAD+ products.
No FDA-approved NAD+ drug is available for wellness, anti-aging, detox, fatigue, cognition, recovery, or clinic-style infusions.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| NAD+ boosts cellular energy. | NAD+ is central to redox metabolism, but the available human work has not shown that commercial NAD+ products reliably improve fatigue, stamina, or daily energy in broad wellness populations. | The NAD+/NADH pair helps move electrons through core energy metabolism, and NAD+ also feeds enzyme systems involved in stress and metabolic signaling. | Clinic and med-spa copy often uses "cellular energy" as the main reason for IV drips, injections, nasal products, or oral products. That language is common, but it is not the same as a controlled clinical outcome. | Solid as basic biology; thin as a practical benefit claim unless a source names the product, route, dose, population, and measured outcome. |
| NAD+ drips or shots are anti-aging therapy. | Current human sources do not show convincing anti-aging outcomes for NAD+ drips, shots, sprays, or oral products. Registry and identity sources do not carry lifespan or healthspan claims. | NAD biology is relevant to aging research because NAD-consuming enzymes, mitochondrial stress, and inflammatory signaling are connected to aging biology. Product-level anti-aging benefit still needs outcome data. | Longevity clinics and wellness pages commonly use anti-aging language, often alongside mitochondrial or biohacking stacks. | The available human data do not include anti-aging outcomes for these products. |
| NAD+ detoxes drugs or treats withdrawal. | Uncontrolled or combined-protocol reports cannot isolate NAD+ as the active factor. A post-COVID registry also combines low-dose naltrexone with NAD+, so it does not isolate NAD+ efficacy by itself. | NAD+ is important to metabolism, but that broad role does not mean an infusion detoxes opioids, alcohol, or other drugs. | Detox and addiction-support claims appear in clinic and commercial material, but the cited evidence is thin for confident treatment claims. | This is a common clinic pitch, but the direct support is thin. |
| NAD+ improves cognition, brain fog, or mood. | Direct published evidence is not strong enough to make a reliable cognition or brain-fog claim. A registered NAD+ combination study can show that the question is being studied, but a registry is not a result. | NAD biology relates to energy metabolism and cellular stress responses, which makes cognitive-interest plausible. Plausible biology is still not evidence that a marketed product improves cognition. | Brain fog, mental energy, and focus claims appear in wellness and post-viral fatigue discussions, often with many other interventions in the background. | It can be discussed as an interest area, but it is not an established effect. |
| IV NAD+ improves health because it changes metabolites. | The Grant pilot gave 750 mg NAD+ by IV infusion over six hours and tracked plasma and urine NAD-related metabolites. Reyna's retrospective clinic-data study used 500 mg IV NAD+ daily for four consecutive days and focused on tolerability and safety markers. Those sources make IV exposure concrete, but they do not substantiate broad wellness, cognition, detox, recovery, or anti-aging benefit. | Metabolite movement is exactly what one would expect when a redox coenzyme and its breakdown products are administered. The hard question is whether that change produces meaningful clinical outcomes. | Infusion clinics often convert metabolite language into wellness benefit language. | Metabolite shifts are documented; broad clinical benefit is not. |
| A COA or purity test makes a NAD+ vial safe for injection. | FDA materials emphasize a different issue: ingredient suitability, supplier controls, finished-product testing, sterile processing, and endotoxin limits matter for products presented for injection or infusion. | The issue here is product route and manufacturing controls, not the NAD+ mechanism. | Vendor pages may show batch analytics or research-use language while the same market creates the impression that the product is ready for human use. | A COA may support a batch-level claim, but it does not answer whether an injectable NAD+ product meets sterile compounding controls, endotoxin limits, finished-product testing, or facility oversight. |
Bottom line
Main takeaway
NAD+ is a real coenzyme your cells genuinely need, which is exactly what makes it easy to sell. The human evidence for the drips and shots is two small studies that measured exposure and tolerability, not benefits.
Keep three markets separate: IV infusions with thin tolerability data, injectable products under FDA sterility warnings, and oral precursors like NR and NMN that actually do have human pharmacokinetic data for raising NAD+ levels.
The anchors are the PubChem identity record, the Grant 2019 and Reyna 2026 IV studies, two ClinicalTrials.gov registrations, and the FDA compounding and warning-letter file. Everything marketed beyond those sources is assertion.
Identity
What it is
NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a dinucleotide coenzyme. It is not built from amino acids, so calling it a peptide is simply wrong; it sits on peptide sites because the market put it there.
Cells burn through NAD+ two ways: as an electron carrier in the redox reactions that make ATP, and as a consumed substrate for sirtuins, PARPs, and CD38-family enzymes. Levels decline with age, partly because CD38 consumption rises, and that decline is the scientific hook the longevity industry hangs everything on.
The product market is a pile of non-equivalent things: IV drips, subcutaneous shots, nasal sprays, oral NAD+ that is largely degraded before absorption, and oral precursors like NR and NMN that feed the salvage pathway and do raise NAD+ levels in human studies. A claim about one of them says nothing about the others.
How people talk about it online
Clinic menus sell NAD+ the way they sell most infusions: energy, focus, recovery, detox, anti-aging, sometimes addiction support. The pricing is real; the outcome data behind those words is not.
Forum culture folds NAD+ into stacks with MOTS-c, SS-31, glutathione, and methylene blue, often alongside diet and training changes. When someone reports feeling better on four of those at once, attribution is anyone's guess.
The two honest bright spots in the oral market are NR and NMN, precursors with actual human pharmacokinetic data showing they raise NAD+ levels. Raising a level and improving a life are still different claims, but at least the first one is measured.
Use context
Routes, doses, and cycle patterns
In practice, keep routes separate and treat injectable quality as a main issue. Small IV studies make some exposures concrete, while commercial sources sell many routes and broader wellness goals. A study exposure, clinic package, nasal product, oral supplement, and gray-market vial are different NAD+ situations, not a single schedule.
Human studies and product labels
Grant 2019 IV NAD+ metabolome pilot
- Purpose
- Route-specific metabolome and pharmacology context
- Context
- Small human pilot
- Route
- Intravenous infusion
- Amount
- 750 mg NAD+
- Frequency
- Single infusion
- Duration
- Six-hour infusion
The Grant pilot is useful because it names a real IV exposure and measured NAD-related metabolites. It was small and was not a wellness-outcome, detox, cognition, recovery, or anti-aging trial.
Reyna 2026 IV NAD+ tolerability pilot
- Purpose
- Real-world infusion tolerability comparison
- Context
- Retrospective clinic-data pilot comparing IV NAD+ with IV NR
- Route
- Intravenous infusion
- Amount
- 500 mg NAD+
- Frequency
- Daily for four consecutive days
- Duration
- Four infusion days with 30-day follow-up
This source describes commercial-setting exposure and tolerability. It reported more infusion discomfort and longer infusion times with IV NAD+ than IV NR, but it was small and retrospective. It is useful for exposure and tolerability context, not broad wellness efficacy.
NAD in immune thrombocytopenia registry
- Purpose
- Disease-specific NAD evaluation
- Context
- ClinicalTrials.gov registry
- Route
- Route not listed in registry
- Amount
- Dose not listed in registry
- Frequency
- Schedule not listed in registry
- Duration
- Duration not listed in registry
This registry shows study interest. It does not support general wellness or clinic-infusion claims.
Low-dose naltrexone plus NAD+ post-COVID registry
- Purpose
- Post-COVID syndrome research question
- Context
- ClinicalTrials.gov registry
- Route
- Route not listed in registry
- Amount
- Dose not listed in registry
- Frequency
- Schedule not listed in registry
- Duration
- Duration not listed in registry
The registry combines low-dose naltrexone with NAD+, so it is not a clean test of NAD+ alone and cannot answer brain fog, fatigue, or recovery benefit.
Real-world discussion
Clinic IV infusion programs
- Purpose
- Energy, longevity, and recovery discussion
- Context
- IV clinics and longevity practices
- Route
- Intravenous infusion
- Amount
- Clinic menus commonly describe 250 to 750 mg per infusion, run slowly over one to four hours; faster rates are consistently associated with nausea and chest pressure in clinic guidance.
- Frequency
- Commonly one to three infusions per week in loading-style programs, then monthly maintenance
- Duration
- Sold as multi-session programs or ongoing memberships
IV NAD+ is the dominant real-world format, and the slow-infusion convention exists because of tolerability, not efficacy data. Human outcome evidence for the marketed benefits is thin. Not verified as a regimen; context only.
Subcutaneous community protocols
- Purpose
- Energy and longevity discussion
- Context
- Forums and vendor listings
- Route
- Subcutaneous injection
- Amount
- Most reports describe 50 to 100 mg per injection
- Frequency
- One to three times weekly in most descriptions
- Duration
- Multi-week runs in community logs
Subcutaneous self-use is a community adaptation of the clinic IV format; injection-site reactions are the most consistent complaint.
Oral precursor supplements
- Purpose
- NAD+ support without needles
- Context
- Retail supplement market
- Route
- Oral capsules
- Amount
- NMN and NR products are commonly marketed at 250 to 1000 mg per day
- Frequency
- Once or twice daily
- Duration
- Ongoing supplement use
Oral precursors are legal supplements with actual human pharmacokinetic data for raising NAD+ levels, which is a different evidence situation from injectable NAD+.
What varies
- Route: keep IV infusion, injectable shots, nasal products, oral products, and research vials separate.
- Amount: small IV sources name 750 mg over six hours and 500 mg daily for four days; those are study exposures, not a universal wellness dose.
- Frequency: a registry can define a research schedule, a clinic package can show a sales pattern, and a personal-use report can only show what someone says they tried.
- Duration: a registry endpoint, a clinic package, and a wellness course do not carry the same confidence about benefit or safety.
- Product controls: sterility, endotoxin burden, ingredient grade, concentration, storage, shipping, labeling, and facility controls matter for injectable or infusion products.
Human data
Human evidence
Two small studies are the whole of it. Grant's 2019 pilot infused 750 mg of NAD+ over six hours and documented the expected shift in NAD-related metabolites. Reyna's 2026 retrospective review of clinic clients given 500 mg IV daily for four days found NAD+ infusions caused more discomfort and took longer than IV NR. Beyond those sit two trial registrations, one in immune thrombocytopenia and one combining low-dose naltrexone with NAD+ after COVID, neither of which isolates NAD+ or reports wellness outcomes. No published human study has tested the anti-aging, cognition, detox, recovery, or energy claims that fill clinic menus.
Evidence maturity
NAD+ sits between real biochemistry and thin outcomes: the decline with age is documented, the benefits of replacing it are not.
Established cofactor for sirtuins, PARPs, and CD38 with documented age-related decline.
NMN and NR raise NAD+ levels in humans; outcome benefits remain unproven.
IV NAD+ programs widespread without controlled outcome data.
FDA sterile-compounding alerts for injectable NAD+ products.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| PubChem identity reference | Chemical identity reference, not a patient population | Chemical database source | Molecule identity | Supports NAD+ as beta-nicotinamide adenine dinucleotide and helps separate the coenzyme from peptide sequences. | Does not test human benefits, routes, doses, frequency, or product quality. | Strong for identity; no efficacy claim |
| FDA injectable and infusion product-quality materials | People evaluating clinic, compounded, or vendor NAD+ products | FDA safety alert, supplier-quality guidance, bulk-substance policy, and warning-letter context | Injectable and infusion NAD+ product-quality risk | FDA materials describe ingredient-suitability, supplier-quality, sterility, endotoxin, adverse-event, and finished-product-control concerns around NAD+ products presented for injection or infusion. | Regulatory materials do not test every clinic product or establish a wellness benefit, route preference, dose, frequency, or duration. | Stronger for product-quality risk than efficacy |
| Grant 2019 IV NAD+ metabolome pilot | Small healthy-adult pilot cohort | Human pilot study tracking plasma and urine NAD-related metabolites | Intravenous NAD+ exposure | A 750 mg NAD+ IV infusion over six hours produced measurable changes in NAD-related plasma and urine metabolites. | Small and pharmacology-focused, rather than designed to test wellness, detox, cognition, recovery, or anti-aging outcomes. | Preliminary human exposure evidence |
| Reyna 2026 IV NAD+ versus IV NR tolerability pilot | Commercial clinic clients in a retrospective review | Retrospective tolerability pilot with 30-day follow-up | Commercial-setting IV NAD+ exposure | Participants received 500 mg IV NAD+ daily for four consecutive days; IV NAD+ was associated with more infusion discomfort and longer infusion times than IV NR. | Small, retrospective, commercially situated, and not an efficacy trial for the wellness claims attached to NAD+ clinics. | Preliminary real-world tolerability evidence |
| NAD in immune thrombocytopenia registry | Immune thrombocytopenia patients | ClinicalTrials.gov registry | Disease-specific investigational context | Shows that an NAD disease question is registered. | Registry information is not a posted efficacy result and cannot carry broad wellness claims. | Trial-tracking context |
| Low-dose naltrexone plus NAD+ post-COVID registry | Patients with post-COVID syndrome | ClinicalTrials.gov registry | Combined-intervention investigational context | Shows a registered post-COVID research question involving low-dose naltrexone and NAD+. | Combination treatment and registry status prevent clean conclusions about NAD+ alone. | Trial-tracking context |
Cautions
Safety and unknowns
- Infusion tolerability can be route- and protocol-sensitive. In the cited material, the clearest safety signal is FDA's report of adverse events after injectable NAD+ use, not a broad comfort or safety profile for clinic protocols.
- Long-term repeated wellness use remains poorly characterized, especially in older adults, people with chronic illness, people with active or prior cancer concerns, pregnancy, lactation, and people stacking multiple mitochondrial or stimulant-adjacent interventions.
- FDA has described adverse event reports after NAD+ injectable use, including severe chills, shaking, vomiting, and fatigue in the sterile-compounding alert.
- FDA warning letters involving compounded NAD+ products show why endotoxin burden and finished-product release testing are not paperwork for injectable or infusion products.
- Direct NAD+ safety conclusions need compound- and route-specific support, not borrowed confidence from NR, NMN, niacinamide, NADH, or general vitamin-B literature.
Product quality
A vial label is only a starting point
Injectable and infusion products require more than a claimed identity or purity percentage. Sterility, endotoxin limits, ingredient grade, concentration, finished-product testing, storage, shipping, and labeling are central.
FDA has specifically warned about food-grade NAD+ being used for sterile compounded products and has described adverse-event and endotoxin concerns in NAD+ product contexts.
A research-use-only vial, COA, or batch-test document leaves open whether a product is a sterile drug, a clinic-quality infusion, or clinically effective.
Identity
NAD+, NADH, NR, NMN, niacinamide, and niacin are related but not interchangeable. The exact compound matters before any route or outcome claim can be read.
Sterility and endotoxin
Endotoxin and contamination risks can dominate the safety profile for injection or infusion products, even when a seller advertises purity.
Ingredient grade
FDA has warned that food-grade ingredients are not necessarily suitable for sterile drug compounding.
Finished-product testing
Raw-material analytics do not replace finished-product release testing, concentration verification, container closure controls, or facility oversight.
Storage and handling
Shipping, storage, reconstitution, and beyond-use dating can affect what a patient or clinic actually receives.
Mechanism
How it is proposed to work
NAD+ helps cells move electrons during energy metabolism and also serves as a consumable substrate for enzymes involved in stress responses, DNA-damage signaling, inflammation biology, and metabolic adaptation.
The NAD+/NADH pair participates in glycolysis, the TCA cycle, and oxidative phosphorylation by carrying reducing equivalents through controlled energy-transfer steps.
Sirtuins, PARPs, and CD38-family enzymes consume NAD+ as part of signaling and repair-related pathways. That explains the aging and mitochondrial interest, but it does not identify the best route or show symptom improvement.
Changing plasma or urinary NAD-related metabolites would not by itself mean that an IV, injectable, nasal, oral, or sublingual product improves symptoms. The available pharmacology is more complicated than simply "refilling cells" with NAD+.
Age-related NAD+ decline has made CD38 inhibition a research target alongside precursor strategies.
The salvage pathway is the practical one: nicotinamide riboside and NMN feed NAD+ synthesis through NRK and NMNAT enzymes, which is why the oral precursor market exists despite NAD+ itself being poorly oral-bioavailable.
FAQ
Common questions
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme. It appears here because peptide clinics, mitochondrial-product catalogs, and wellness vendors often discuss it beside peptides.
Does this support NAD+ infusion or injection protocols?
No. It describes patterns from studies and market discussion while keeping clinic, compounded, and vendor claims separate from evidence of benefit.
Details
Technical details
Sources
References
- 1.
Other. PubChem Compound Summary for beta-Nicotinamide adenine dinucleotide 2026.
Accessed 2026-06-09.
NIH PubChem identity source for beta-nicotinamide adenine dinucleotide; used to separate NAD+ chemical identity from peptide sequence records and intervention claims.
- 2.
FDA. FDA reminds compounders to use ingredients suitable for sterile compounding 2024.
Accessed 2026-06-09.
FDA alert describing ingredient-suitability concerns for sterile compounded products, including NAD+ examples and reported adverse events consistent with endotoxin-related reactions.
- 3.
FDA. FDA to Compounders: Know Your Bulks and Excipients Suppliers 2026.
Accessed 2026-06-09.
FDA supplier-quality guidance for compounders; used for product-quality context, not as evidence of NAD+ efficacy or route instructions.
- 4.
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A 2026.
Accessed 2026-06-09.
FDA 503A nominated bulk-substance category document listing nicotinamide adenine dinucleotide context; this is compounding policy context, not finished-product approval.
- 5.
FDA. 503B Bulk Drug Substances List 2023.
Accessed 2026-06-09.
FDA 503B bulk-substance list context for outsourcing facilities; used to distinguish compounding policy status from product approval or clinical evidence.
- 6.
FDA. GenoGenix LLC warning letter 2026.
Accessed 2026-06-09.
FDA warning letter discussing NAD+ compounded drug products and 503B exemption conditions; used for regulatory context.
- 7.
ClinicalTrials.gov. A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia 2026.
NCT06776510 Accessed 2026-06-09.
Registry source for a disease-specific NAD research question; used as trial-tracking context, not support for wellness or infusion claims.
- 8.
ClinicalTrials.gov. Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome 2026.
NCT04604704 Accessed 2026-06-09.
Registry source for a low-dose naltrexone and NAD+ post-COVID study; used as trial-tracking context without publishing protocol or dose instructions.
- 9.
PubMed. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD 2019.
PMID:31572171 Accessed 2026-06-17.
Small human IV NAD+ metabolome pilot; used for study-exposure context, not as evidence of wellness efficacy.
- 10.
PMID:41704678 Accessed 2026-06-17.
Retrospective clinic-data pilot comparing four consecutive days of IV NAD+ with IV NR; used for real-world study-exposure and tolerability context.
- 11.
Recharged Functional Wellness NAD+ page. Clinic page listing IV, intramuscular, and at-home subcutaneous NAD+ products and schedules.
Direct clinic evidence for IV, IM, and subcutaneous market patterns
- 12.
ZYP NAD+ therapy menu. Telemedicine clinic page listing direct NAD+ oral capsules, sublingual tablets, and nasal spray.
Direct market evidence that non-IV direct NAD+ products are sold across several routes
- 13.
Secra Labs NAD+ research vial. Vendor listing for a 500 mg lyophilized NAD+ research-use-only vial.
Direct vendor evidence for RUO vial strength, format, price, and non-clinical positioning